We reviewed clinical and radiographic data on 73 patients evaluated for possible Marfan syndrome (MFS) at the National Institutes of Health for the purpose of comparing the 1987 Berlin and 1996 Gent diagnostic criteria. All patients had a physical examination, all had echocardiograms or known aortic root dilatation, 64 (88%) had ophthalmologic exams or known ectopia lentis, and 35 (48%) have had MRI scans to screen for dural ectasia. Thirty-one had a first degree relative who had been diagnosed with MFS, and we directly confirmed this diagnosis in 22 cases. Forty-eight patients met diagnostic criteria under the Berlin criteria and 39 under the Gent criteria (kappa correlation coefficient K=0.75). No patient who met diagnostic criteria under the Gent criteria failed to meet the Berlin criteria. Of patients diagnosed under the Berlin criteria, all had skeletal features of MFS. 40 (83%) had aortic root dilatation. 19 of 27 examined (70%) had dural ectas~a. 27 (56%) had an affected first degree relative. and 12 of 44 examined (27%) had ectopia lentis. Determination of dural ectasia established the diagnosis for 9 patients under the Gent criteria but had no effect on diagnoses made under the Berlin criteria (K=0.53 comparing Berlln to Gent without dural ectasia data) In summary, approximately 20 percent of patients diagnosed with Marfan syndrome using the Berl~n criter~a do not meet the Gent d~agnostic standard. Long term follow-up or molecular d~agnostic data are necessary to establish the relative sensitivity and specificity of these d~agnostic tools. facial dysmorphism, atrial (ASD) and ventricular (VSD) septa1 defects, contracttons of fingers, tight hamstrings, developmental delay. Sib #2, (2 months) -small stature, ASD, hypotonia, primary optic nerve hypoplasia. Only 4 patients with distal 5 q deletions have been reported and none showed the putative breakpoints identified in our 2 patients. All 6 showed developmental delay; 4 of 6 had defects of cardiac septation. Our 2 patients and 1 other were shown to have only one copy of the cardiac specific hCSX gene which defines in part the etiology o f their ASD and VSD. Isolated mutattons of the hCSX gene encoding homeobox transcription factor NKX2-5 have been shown to produce nonsyndromic septatlon defects (ASD) in 4 families. Deleted contiguous genes may account for other phenotypic features in our patlents BRCA testlng uptake and panlcipatlon in ovarian cancer prevention In women at risk for an inherited ovarian cancer susceptibility. Scheuner M T . Chene LS-C. Hixos HEC. Rotter JI Cedars-Sina~ Medical Center. Los Angeles. CA.
The aim of this study was to assess BRCA testing uptake In women with a family history suggestive o f an lnhented ovarian cancer risk, and to evaluate their participaoon In preventive measures including bilateral salp~ngo-oophorectomy (BSO). screening with tmnsvag~nal ultrasound (TVUS) and serum CA125, and chemoprevention wlth oral contraceptives (OCPs). From January 1998 through June 1999. 112 women received genetlc nsk assessment and counseling regarding a possible inherited susceptibil~ty lo ovarian and related cancers. 62% were Jewish and 42% had a history o f breast cancer. Of these 112 women. 72% elected to participate In BRCA tesllng: deleterious mutations were identified In 22% (18181). Jewish patien& represented 79% of the subjects who chose to undergo test~ng, and included 93% (64169) of all Jew~sh patienls. Only 40% (17143) o f non-Jewish patients chose testlng. Almost all (89%) of the 18 deletenous mutations identified were in Jewish patients; 25% (16164) of Jews who were tested had deleterious mutations compared to only 12% (U17) of nonJews. Jewish patlents were more l~kely than non-Jews to have a personal hlslory of breast cancer. 52% (33169) compared to 26% (1 1/43). p<0.03. Follow-up regarding partlclpatlon In prevenllve services was available for 18 of 22 women seen In [he past 3 yean who had both intact ovaries and deletenous BRCA mutations 10 o f the 18 women underwent BSO, and 7 are participating in TVUS and CAI25 andlor are taklng OCPs for ovanan cancer prevention. Only 3 women had been participallng In ovarian cancer screening prior to the~r genetic consultat~on, and none were taking OCPs for chernoprevention. Age and personal hlstory of breast cancer d~d not dlstlngulsh between those who did and d~d not elect BSO 9 of the 13 Jewlsh women (69%) w~t h a BRCA mutauon had BSO. as did I of 2 non-Jewlsh women These preliminary data suggest [hat women w~l h BRCA mutauons participate in appropnale preventive strategies for ovarian cancer; most chooslng prophylactic BSO. Jewlsh patlents were more l~kely to undergo BRCA testlng [han non-Jewish patlents, th~s m~g h t be due to the increased mutation detect~on rate and reduced cost of testlng. Thus at thls time. genetic risk assessment and testing appears l o be most beneficial for Jewlsh women at r~s k for an Inherited suscept~b~l~ly to ovanan cancer Genetics IN m i c i n e
